Does Blue Cross Blue Shield Cover Wegovy?
The verdict
Conditional on most plans
Blue Cross Blue Shield is a federation of more than 33 independent affiliates with no single Wegovy coverage answer; the deciding variables are which specific affiliate you have, what employer benefit design applies, and what that affiliate's current formulary says. The 2025–2026 trend across the federation has been toward exclusion or restriction of weight-loss GLP-1s — several major Blue plans have dropped or tightened coverage. Medicare covers the cardiovascular indication only across all plans; the Medicare GLP-1 Bridge offers weight-loss access at $50/month from July 1, 2026.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield using your member ID.
Key facts
Blue Cross Blue Shield is a federation of more than 33 independent affiliates — there is no single national Wegovy formulary; each affiliate sets its own policy.
Blue Cross Blue Shield Association — About BCBS
Multiple BCBS affiliates dropped or restricted weight-loss GLP-1 coverage in 2024–2025, including Independence Blue Cross (1/1/2025), BCBS of Michigan (1/1/2025), and Blue Shield of CA (BMI ≥40 new-start rule from 1/1/2025).
KFF — Employer Health Benefits Survey and GLP-1 coverage tracking
Medicare Part D cannot cover Wegovy for weight loss by statute; the $2,100 beneficiary OOP cap applies in 2026 for other Part D-covered medications.
CMS.gov — Medicare Part D benefit parameters 2026
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Across all BCBS affiliates, Medicare Part D cannot cover Wegovy for weight loss by statute. BCBS Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication (established CVD + overweight/obese status) with prior authorization. The Medicare GLP-1 Bridge, launching July 1, 2026 through December 31, 2027, gives eligible Medicare beneficiaries weight-loss access to Wegovy at $50/month outside the Part D benefit — the $50 copay does not count toward the $2,100 OOP cap or TrOOP, and Extra Help cannot be applied. Bridge eligibility criteria: BMI ≥35; or ≥30 with heart failure, uncontrolled hypertension, or CKD; or ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already on a Part D-covered GLP-1 are not eligible. NovoCare savings card not available to Medicare beneficiaries. Verify your specific Blue plan's Medicare PA criteria on that affiliate's plan drug list.
Commercial / Employer
Group & marketplace plans
Coverage on BCBS commercial and employer plans is entirely affiliate-specific and employer-dependent. The trend across the federation for 2025–2026 is strongly toward exclusion or restriction: Florida Blue (BCBS of Florida) excludes weight-loss drugs under a standing commercial GLP-1 policy. Independence Blue Cross (Pennsylvania) excluded Wegovy for fully insured group and individual plans effective January 1, 2025. BCBS of Michigan ended weight-loss GLP-1 coverage for fully insured large-group plans effective January 1, 2025. Blue Shield of California restricts new weight-loss starts to BMI 40 or higher (Class III obesity) since January 1, 2025 — a partial carve-out rather than full exclusion. CareFirst BlueCross BlueShield (Maryland/DC) covers large-group commercial but explicitly excludes ACA/individual plans. Affiliate plans that still cover Wegovy for weight loss typically require employer opt-in and prior authorization (BMI ≥30 or ≥27 with a comorbidity, documented lifestyle program, ≥5% weight loss for renewal). ACA/individual plans are increasingly excluded across the federation. Commercially insured members whose specific Blue affiliate plan covers Wegovy may use the NovoCare savings card ($25/month, max $100/28-day supply); not available to Medicare or Medicaid. Use the affiliate's drug-lookup tool to verify your specific plan.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price, 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period (through December 31, 2026).
List price with no coverage — before any manufacturer savings card.
With coverage
Plan- and affiliate-specific cost-share. NovoCare savings card: commercially insured members whose affiliate plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries. Verify your specific tier and cost-share on your affiliate's drug-lookup tool.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month for eligible Medicare beneficiaries from July 1, 2026 through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap or TrOOP.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Verify actual cost-share through your specific Blue affiliate's member portal. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Identify your specific Blue affiliate
Your insurance card will name the specific Blue affiliate administering your plan — for example, Blue Shield of California, Independence Blue Cross, or BCBS of Michigan. That affiliate, not a national BCBS entity, sets your formulary and PA rules. Each affiliate has its own drug-lookup tool and member portal.
- 2
Search your affiliate's formulary for Wegovy
Use your specific Blue affiliate's drug-lookup or formulary search tool with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to see the current tier, PA status, and any quantity limits. Be aware that several affiliates have updated their GLP-1 policies for 2025–2026 — an old search result may not reflect the current status.
- 3
Confirm employer benefit design with HR
On commercial employer plans, weight-loss drug coverage depends on whether your employer purchased the anti-obesity benefit. Ask HR directly whether anti-obesity medications are included in your plan design. A benefit exclusion cannot be resolved through a prior-authorization or appeals process. If excluded, discuss self-pay options with your prescriber.
Options if Blue Cross Blue Shield won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Your specific Blue affiliate page
This page covers the full BCBS federation with no single answer. For coverage details specific to your plan, find your affiliate's page — for example, Blue Shield of California, BCBS of Michigan, BCBS of Texas, or CareFirst — in the drug-insurance directory.
NovoCare self-pay program
NovoCare Pharmacy offers Wegovy at approximately $349/month without insurance coverage, after an introductory period. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Medicare GLP-1 Bridge (Medicare members)
Starting July 1, 2026, eligible Medicare beneficiaries on any Blue Medicare Advantage plan can access Wegovy for weight loss at $50/month through the Bridge program, operating outside Part D.
Compounded semaglutide
Compounded semaglutide is available without insurance across all BCBS affiliate situations. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
There is no single answer — BCBS is a federation of more than 33 independent affiliate plans, each with its own Wegovy policy. The 2025–2026 trend is strongly toward excluding or restricting weight-loss GLP-1s: Florida Blue excludes them under a standing policy, Independence Blue Cross and BCBS of Michigan dropped them in 2025, and Blue Shield of California restricts new starts to BMI 40 or higher. Some affiliates still cover it with employer opt-in and prior authorization. You must identify your specific Blue affiliate and check that plan's formulary.
Several Blue affiliates have reduced or eliminated Wegovy weight-loss coverage in 2024–2026. Florida Blue excludes weight-loss drugs under a standing commercial policy. Independence Blue Cross (Pennsylvania) excluded Wegovy for fully insured group and individual plans effective January 1, 2025. BCBS of Michigan ended weight-loss GLP-1 coverage for fully insured large-group plans effective January 1, 2025. Blue Shield of California restricts new starts to BMI 40 or higher since January 1, 2025. This is not an exhaustive list — verify your specific affiliate's current policy.
No BCBS Medicare Advantage plan can cover Wegovy for weight loss — that exclusion is statutory for Medicare Part D. BCBS Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication with prior authorization. Starting July 1, 2026, eligible Medicare beneficiaries can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge, which operates outside Part D and does not count toward the $2,100 OOP cap.
This page covers the BCBS federation as a whole and provides the no-single-answer framing. Specific affiliate pages (Blue Shield of California, BCBS of Michigan, BCBS of Texas, CareFirst, etc.) give the policy details for that particular Blue plan. If you know your affiliate, use their specific page for more precise PA criteria, cost information, and formulary guidance. Your insurance card will name your affiliate.
Commercially insured members whose BCBS affiliate plan covers Wegovy can use the NovoCare savings card to pay as little as $25/month (max $100 savings per 28-day supply). The card is not available to Medicare Advantage or Medicaid beneficiaries under federal anti-kickback rules. If your Blue plan excludes Wegovy, the NovoCare self-pay option (approximately $349/month) is available regardless of coverage status.
Related Articles
Does SummaCare Cover Wegovy? 2026 Coverage Guide | Curex
SummaCare covers Wegovy only where your employer opted in; not published. Medicare Advantage covers CV indication; Bridge $50/mo from July 2026.
Read moreDoes Highmark Cover Wegovy? Policy J-0184 Guide | Curex
Highmark covers Wegovy with prior auth under anti-obesity policy J-0184, with tightening for some 2026 groups. Medicare CV indication governed by J-1370.
Read moreDoes SelectHealth Cover Wegovy? 2026 Guide | Curex
SelectHealth covers Wegovy with PA where the plan includes the benefit: BMI 30+ or 27+ with comorbidity, documented prior weight-loss attempts.
Read moreDoes BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes Independence Blue Cross Cover Wegovy? 2026 | Curex
Independence Blue Cross excluded weight-loss GLP-1 coverage 1/1/2025 on fully insured group and individual plans. Only diabetes and CV indications remain.
Read moreDoes Medica Cover Wegovy? Upper Midwest Guide 2026 | Curex
Medica covers Wegovy for weight loss only where your employer opts in — formulary not publicly published. Verify via Medica drug lookup. Medicare CV only.
Read moreWhether or not Blue Cross Blue Shield covers Wegovy, there's a path that skips insurance
You just saw how tangled Wegovy coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Wegovy. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.